Skip to main content
. 2018 May 25;9(6):637. doi: 10.1038/s41419-018-0685-8

Fig. 4. ANXA5 suppression reduces in vivo tumorigenicity and LNM rate of Hca-P.

Fig. 4

The influence of ANXA5 suppression on in vivo tumor formation volume and mass for mice transplanted with Hca-P-ANXA5-shControl and Hca-P-ANXA5-shRNA1 cells in 10 (a) and 21 (b) days. Tumor volume (V) was calculated as length × width × depth × π/6. Tumorigenicity of Hca-P-ANXA5-shRNA1 was decreased than Hca-P-ANXA5-shControl with **P < 0.01. ANXA5 suppression decreases LNM malignancy and rate of tumor cell-bearing mice. The mass reductions of popliteal and inguinal LNs from Hca-P-ANXA5-shRNA1-tansplanted mice in c 10 and d 21 d following transplantation are of stastical significance than control group mice (P < 0.05). Data are expressed as mean ± S.D. e Popliteal and inguinal LNs with H.E staining. There were few morphological changes of the Hca-P-ANXA5-shRNA1-transplanted mice, including the chromatin condensed in border and the pathological karyokinesis reduced obviously than Hca-P-ANXA5-shControl-transplanted mice. The metastatic LNs from Hca-P-ANXA5-shControl-transplanted mice became more vague and abnormal on 21st d than LNs from Hca-P-ANXA5-shRNA1-transplanted mice